Overview

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

Biliary tract cancer (BTC) presents with a 5-year survival rate less than 5%. The goal of this clinical trial is to evaluate if Anlotinib plus Nab-Paclitaxels and S-1 as second-line regimen can improve the treatment efficacy in advanced biliary tract cancer (BTC) after progression upon first-line standard treatment, in comparison with standard second-line FOLFOX regimen.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

CTTQ Pharma

Treatments:

Albumin-Bound Paclitaxel
anlotinib
Fluorouracil
Folfox protocol
Leucovorin
Oxaliplatin
S 1 (combination)
tegafur-gimeracil-oteracil